Vector Engineering Clinical: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Vector Engineering Clinical (NCT04725500), a na na study. The primary outcome is Average EPAP During Overnight PSG.

2. Clinical Question

3. Trial Design

The registry describes a prospective, non-randomized, single-group device study in stable participants with COPD. It lists the study as completed and reports enrollment of 42. The study dates in the record are 2018-10-04 for the start and 2020-03-03 for primary completion. The phase and allocation are listed as NA, consistent with a device evaluation rather than a conventional randomized drug comparison. Masking is listed as none.

Participants underwent an overnight sleep-laboratory assessment using the auto-titrating EPAP mode. The primary endpoint focused on average EPAP during approximately 8 hours of PSG. The device’s intended operating behavior was to adjust EPAP to the minimum value able to abolish expiratory flow limitation. This study structure can describe device use within the enrolled group, but without a separate comparison group it cannot estimate a between-group treatment effect.

The registry summary also describes home use for a 2 week period in a subgroup. EPAP behavior during this period was assessed, and secondary outcomes included sleep quality, 2 Week Home Use Device Compliance, and a therapy comfort survey. The number of participants in that subgroup and the associated outcome results are not reported in the registry record.

Seven outcome measures are listed, but the record reports zero analyses. It does not report a statistical analysis plan, a sample-size justification for the trial, or details of interim analyses. The sample-size planning illustration associated with the record is distinct from the study’s enrollment: it uses stated assumptions and an effect based on the observed effect, rather than documenting how enrollment of 42 was chosen. No randomized comparison, control condition, or masking procedure should be inferred from this design.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Screening

Reasons for not completing this period:

Overnight Polysomnography (PSG)

2 Week Take Home

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: PSG data was not available for one participant.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: All participants that signed a consent form.

6. Primary Endpoint

The registry lists the primary outcome as Average EPAP During Overnight PSG, measured over Approximately 8 hours.

The primary endpoint is average expiratory positive airway pressure (EPAP) during overnight polysomnography (PSG), with the measurement reported in cmH2O. The stated timeframe is approximately 8 hours. EPAP is the device parameter that automatically changes during use. In this study, the mode was intended to titrate EPAP to the minimum value able to abolish expiratory flow limitation (EFL).

Following the average EPAP over the overnight recording provides a summary of the pressure level used during that assessment. In general, a mean reduces a sequence of measurements to one central value; by itself, it does not show how much the pressure fluctuated over the night, when adjustments occurred, or how many participants had values far from the group average. Those questions would require additional descriptive results or analyses, which are not reported in the registry record.

The endpoint is relevant to the stated engineering evaluation because it concerns the behavior of the automatically adjusted parameter during device use. It is not, by itself, a measure of a clinical benefit, a comparison with another device, or a long-term outcome. The record says PSG data were unavailable for one participant. It does not report the observed mean or standard deviation, so the central result and its variability cannot be interpreted from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The primary endpoint is a continuous measurement: average EPAP during overnight PSG. For a continuous outcome, the mean describes the central level of the measurements, while the standard deviation describes how dispersed individual measurements are around that mean. These summaries answer different questions. A mean does not tell readers how similar participants’ values were; a standard deviation does not describe the uncertainty in the mean. The registry record specifies mean and standard deviation as the intended summaries, but reports neither numerical value.

In general, a confidence interval gives a range of estimates compatible with the data and the chosen statistical procedure. Its width reflects both the amount of information and the variability in the observations. It is not a guarantee that the true value lies within that particular interval, nor does it show the range of individual participant values. No confidence interval for average EPAP is reported in the registry record, so its precision cannot be assessed.

The study has a single-group structure. That means its primary endpoint can be described for participants who used the auto-titrating mode, but there is no concurrent control group in the record for a treatment contrast. In general, a comparison group can help distinguish differences associated with the intervention from changes or influences that may occur regardless of it. Random allocation can also reduce systematic differences between comparison groups. Neither a randomized allocation nor a separate comparison arm is reported for this study. The available design therefore supports a device-use description, not a randomized comparative estimate.

The registry’s sample-size planning illustration is not a record of how this trial was designed or enrolled. It is described as a planning exercise based on the observed effect, with two-sided significance level 0.05, equal allocation between two arms, and a normal approximation. It considers the effect to detect as a stated fraction of the observed effect. Such an illustration answers a hypothetical planning question under its assumptions; it does not establish that the study used those assumptions, and it does not measure the probability that the completed study detected an effect. Sample sizes in a planning illustration are planning quantities, not observed trial findings. Because the registry record does not report the observed primary effect, no numerical planning result can be interpreted from the information recorded.

In general, a two-sided significance level sets a decision threshold for a hypothesis test that allows departures in either direction from a null value. The normal approximation is a mathematical approach that may be used to estimate sampling behavior. Equal allocation is an assumption about how participants would be divided between two hypothetical arms. Those assumptions do not describe the single-group study itself, and the planning illustration should not be read as evidence that two arms were enrolled.

The primary endpoint is an average over a night, but the record does not describe the measurement-level analysis in detail. It does not state whether pressure was summarized across time points, how recording intervals were handled, or what model was used. Such details can matter when repeated readings from the same participant are correlated. Treating every repeated reading as independent would generally understate uncertainty if within-participant observations are related; a suitable repeated-measures method can account for that dependence. The registry record does not report whether repeated readings were analyzed individually or only summarized for each participant.

Over-dispersion is a general issue for count outcomes when observed variation exceeds what a simple count model expects. It can affect standard errors and confidence intervals if not accounted for. The primary endpoint in this study is continuous, not a count, and the record gives no analysis details that would indicate an over-dispersion issue for it. The safety figures are counts, but no inferential model for those counts is reported. No specialized model or adjustment should be assumed.

The record lists seven outcome measures and zero analyses. It does not report which statistical tests, models, covariates, or estimation procedures were used. It also does not report a protocol-defined sample-size justification, interim analyses, or a plan for handling multiple outcomes. Without those details and without posted endpoint estimates, readers cannot reproduce or assess an inferential analysis. The central statistical reading is therefore descriptive: the endpoint and its intended summaries are specified, but the observed result and its uncertainty are not available in the registry record.

10. Confidence Intervals for Each Arm

No two-arm comparison is shown for this trial, but each arm's mean can be given with a t-based 95% confidence interval computed from the posted mean, spread and number of participants.

R code and output

arm <- c("Auto-titrating EPAP")
n   <- c(14)
m   <- c(9.5)
sp  <- c(5.4)
sd  <- sp      # posted standard deviations
for (i in seq_along(n)) {
  se <- sd[i] / sqrt(n[i]); h <- qt(0.975, n[i] - 1) * se
  cat(sprintf("CARM|%s|%d|%.3f|%.3f|%.3f|%.3f\n", arm[i], n[i], m[i], sd[i], m[i] - h, m[i] + h))
}

CARM  Auto-titrating EPAP  14  9.500  5.400  6.382  12.618

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists seven outcome measures, including the primary overnight EPAP measure and secondary outcomes related to sleep quality, home-use device compliance, and therapy comfort. It reports zero analyses. No statistical analysis plan or multiplicity procedure is reported in the registry record. It is therefore not possible to tell whether the study intended to treat one endpoint as confirmatory and the others as exploratory, or how it would have controlled the chance of false-positive findings across multiple tests.

In general, multiplicity arises when several outcomes or hypotheses are examined. If each is tested separately without an adjustment or a prespecified hierarchy, the chance of at least one apparently positive result can increase. Methods such as adjusting significance thresholds or specifying an ordered testing strategy can address this issue, but the record does not say whether any such approach was planned or used. Since no analyses are listed, there are no posted hypothesis-test results to interpret in light of multiplicity.

For missing data, the record specifically notes that PSG data were unavailable for one participant. It does not state why the recording was unavailable, whether the participant contributed to other outcomes, or whether any imputation or sensitivity analysis was performed. It also does not define an analysis population or report the exact number analyzed for the primary endpoint. The size of the home-use subgroup is not reported, and missingness for the secondary outcomes is not described.

In general, missing-data methods depend on why measurements are absent and on what assumptions can reasonably be made about the unobserved values. Complete-case analysis, imputation, and sensitivity analysis answer questions under different assumptions; none should be attributed to this study without documentation. The registry record does not report those methods, so the effect of missing observations on the endpoint estimate cannot be assessed.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: alcohol detox (2.4%).

The registry safety summary lists the auto-titrating EPAP group with 42 participants at risk for serious adverse events and 1 affected. It lists 42 at risk for other adverse events and 3 affected. Deaths are reported as 0. The most frequently listed serious-event term is Alcohol detox, at 2.4%.

These figures should be read as descriptive registry counts, not as a comparison with another group. The study has no separate comparator arm, and the record does not report event-level details, timing, severity beyond the serious-versus-other classification, or an assessment of relatedness to the device. The listed figures alone therefore cannot establish whether an event was caused by use of the device or whether the event rate differs from what would otherwise have occurred.

The specific term Alcohol detox is a registry classification. The record does not provide the clinical circumstances needed to interpret that term, and it should not be taken as evidence of a device-related event. Likewise, 0 deaths is the count reported for this study; it does not establish a general safety profile. Safety interpretation is limited by the single-group design and the level of detail recorded.

13. What the Result Does, and Does Not, Mean

The registry record describes an engineering evaluation of a mode that automatically adjusts EPAP during NIV use in participants with COPD. Its primary question concerns the behavior of average EPAP during an overnight PSG assessment, over approximately 8 hours. This focus is aligned with the stated device function: titrating pressure to the minimum value able to abolish expiratory flow limitation.

That description does not amount to a reported result. The registry record does not give the observed average EPAP or its standard deviation, and it reports zero analyses. There is consequently no numerical estimate or uncertainty interval available to judge how the pressure behaved across the study group. The absence of a posted estimate does not mean that the device did or did not achieve its intended behavior; it means that this record does not report the numerical evidence needed to evaluate that question.

The single-group, non-randomized design can offer information about use in the participants who were assessed, but does not provide a direct comparison with another NIV mode or a control condition. It cannot, on its own, attribute observed differences to the device or establish a comparative treatment effect. The record also does not report longer-term clinical outcomes. A short overnight measurement and a described 2 week home-use subgroup do not, without posted results, establish longer-term effects.

The study enrolled 42 participants, and PSG data were unavailable for one participant. The record does not explain how that missing recording was handled. Home-use subgroup size and secondary outcome estimates are also not reported. These omissions limit conclusions about the completeness and representativeness of the analyzed data.

Thus, the evidence in the registry record is informative about the study’s aim, endpoint, and design, but not about the magnitude or precision of the primary result. The safety counts are also descriptive and do not establish causation. No conclusion that the device works or does not work is warranted from the information recorded.

14. Why This Trial Matters Statistically

This study raises a useful statistical distinction between measuring device behavior and demonstrating a comparative clinical effect. The primary endpoint concerns the pressure automatically selected during overnight use. That can address whether the device’s operation was characterized during a sleep-laboratory assessment, but it is not a comparison with another mode. The single-group design should therefore shape the questions asked of the data.

Reporting the endpoint definition is important, but a definition alone does not reveal the result. The registry identifies average EPAP, its unit, intended summary statistics, and timeframe. Without the observed mean, standard deviation, or an interval estimate, readers cannot judge the pressure level, variability across participants, or precision of the group estimate. The distinction between a planned measurement and a reported estimate is central to statistical interpretation.

The missing PSG recording also highlights why analysis populations and missing-data handling matter. Even when the number of unavailable measurements is stated, readers need to know how those observations were addressed and how many participants contributed to each result. The registry record does not report those details. Similarly, listing multiple outcomes without analyses or a multiplicity plan leaves uncertainty about how outcomes were prioritized and interpreted.

Finally, the planning illustration should not be confused with the completed study’s design or with observed power. Its assumptions describe a hypothetical two-arm calculation, while the trial is recorded as single-group. Keeping planning assumptions separate from trial evidence helps prevent a numerical exercise from being mistaken for a result. Overall, this record illustrates how clear endpoint definitions and design descriptions are necessary, but not sufficient, for a complete statistical interpretation.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting the registry record is that it does not report the primary outcome estimate. Average EPAP and its standard deviation are identified as the intended endpoint summaries, but the numerical findings and any measure of precision are absent. The record also lists zero analyses, so no inferential results are available for assessment.

The single-group, non-randomized design has no separate comparator. It can describe measurements during use of the auto-titrating mode, but cannot support a direct estimate of how those measurements differ from another device or mode. Masking is listed as none. The record does not describe procedures that might reduce measurement or assessment bias.

PSG data were unavailable for one participant, but the reason, analysis handling, and number contributing to the primary estimate are not reported. The registry does not specify an analysis population, missing-data methods, or sensitivity analyses. The home-use subgroup’s size is also not reported, limiting interpretation of the described 2 week assessment.

The record lists seven outcome measures but does not report analyses, a multiplicity strategy, or a statistical analysis plan. It also does not report a study-specific sample-size justification, interim analyses, or detailed methods for handling repeated measurements. These omissions prevent assessment of whether the analyses followed a prespecified approach. The safety information is limited to counts and a leading serious-event term; event timing, context, and relatedness are not reported. These limitations concern what can be concluded from the registry record and should not be read as evidence for or against the device.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Vector Engineering Clinical — NCT04725500.
• Registry record last updated 2021-05-26; status last verified 2021-05.
• Results first posted 2021-04-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a completed prospective, non-randomized, single-group evaluation of auto-titrating EPAP in stable participants with COPD. Enrollment was 42. Participants were assessed in a sleep laboratory during one night, with the primary endpoint defined as average EPAP during approximately 8 hours of PSG. A subgroup also used the device at home for a 2 week period.

The record specifies the primary endpoint and its intended mean and standard deviation summaries, but does not report their values. PSG data were unavailable for one participant. Seven outcome measures are listed, with zero analyses reported. The home-use subgroup size and its outcome results are not reported in the registry record.

The safety summary reports 1 serious adverse event affected among 42 at risk, 3 other adverse events affected among 42 at risk, and 0 deaths. Alcohol detox is listed as the top serious-event term, at 2.4%. These are descriptive figures without a comparator or reported event attribution.